No, Vyzulta and Rhopressa (netarsudil) are NOT in the same drug class
Vyzulta (latanoprostene bunod) is classified as a prostaglandin analog, while Rhopressa/netarsudil (the active ingredient in Zolymbus) is classified as a Rho kinase (ROCK) inhibitor 1, 2.
Key Distinctions Between the Two Medications
Vyzulta (Latanoprostene Bunod)
- Drug Class: Prostaglandin analog with nitric oxide-donating properties 2
- Mechanism: Rapidly metabolized to latanoprost (a prostaglandin F2α analog) and butanediol mononitrate (nitric oxide donor), enhancing aqueous outflow through both uveoscleral and trabecular meshwork pathways 1, 2
- IOP Reduction: Comparable to other prostaglandin analogs
- Common Side Effects: Conjunctival hyperemia, increased iris pigmentation (typical of prostaglandin class)
Netarsudil (in Zolymbus/Rhopressa)
- Drug Class: Rho kinase (ROCK) inhibitor 1
- Mechanism: Increases trabecular outflow, decreases episcleral venous pressure, and decreases aqueous production 1
- IOP Reduction: 10-20% 1
- Common Side Effects: Conjunctival hyperemia, corneal verticillata, instillation site pain, conjunctival hemorrhage, keratitis 1
Clinical Implications
While both medications can cause conjunctival hyperemia, they work through fundamentally different mechanisms and belong to distinct pharmacologic classes. Netarsudil represents a novel class of glaucoma medications that directly targets the trabecular meshwork outflow pathway, whereas Vyzulta is essentially an enhanced prostaglandin analog that combines traditional prostaglandin effects with nitric oxide donation 3, 4.
Important Caveat
The fact that these are different drug classes means they can potentially be used together or sequentially without redundancy in mechanism of action. However, netarsudil is also available in a fixed-dose combination with latanoprost (Rocklatan), which would overlap mechanistically with Vyzulta's prostaglandin component 5, 6.